Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-31

Clinical Trial Update: Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating semaglutide as an adjunct to dieting for type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • semaglutide (semaglutide)

Snippet

Sponsor: Kirsi Pietiläinen | Conditions: Type2 Diabetes | Phase 4 | Status: UNKNOWN